Ivacaftor/lumacaftor - Vertex Pharmaceuticals
Alternative Names: Ivacaftor/VX-809; Lumacaftor/ivacaftor; ORKAMBI; Orkambi; VX-770/VX-809; VX-809/ivacaftor; VX-809/VX-770Latest Information Update: 04 Oct 2023
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
- Developer Vertex Pharmaceuticals
- Class Amides; Aminophenols; Antifibrotics; Benzodioxoles; Benzoic acids; Cyclopropanes; Pyridines; Quinolones; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cystic fibrosis
Most Recent Events
- 22 Aug 2023 Vertex Pharmaceuticals completes a phase III trial in Cystic fibrosis (In infants, in children, in adolescents, in adults) in Canada and the US (NCT04235140)
- 05 Jul 2023 Registered for Cystic fibrosis (In infants) in Liechtenstein, Iceland, Norway, European Union (PO)
- 10 Apr 2023 Launched for Cystic fibrosis (In infants) in Canada (PO)